-
Itraconazole B2104 for Reliable Cell Assays
2026-09-03
Itraconazole (SKU B2104) offers a practical, data-grounded framework for antifungal, cell viability, and drug-interaction experiments. This scenario-based guide addresses solubility, biofilm resistance, assay controls, concentration interpretation, and vendor selection using product specifications and recent Candida research.
-
Oltipraz Workflows for MASLD Nrf2 Research
2026-09-03
Oltipraz provides a defined Nrf2-activating tool for connecting phase II enzyme induction with autophagy and ferroptosis assays in liver disease models. This workflow shows how to distinguish direct redox-pathway activity from broader effects reported for Qushi Huoxue ointment while improving dosing, controls, and troubleshooting.
-
CX-4945 (Silmitasertib): CK2 Cancer Research
2026-09-02
CX-4945, also called Silmitasertib, is an ATP-competitive CK2 inhibitor used to investigate CK2-dependent signaling, apoptosis, and context-specific cell-cycle control. Product and peer-reviewed evidence support its use as a mechanistic research tool, but cellular and xenograft findings do not establish a universal clinical anticancer effect.
-
Exemestane: From Mechanism to Translation
2026-09-02
A translational framework for using Exemestane as a steroidal aromatase inhibitor, connecting irreversible enzyme inactivation with model selection, assay design, biomarker strategy, and breast cancer research decisions.
-
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-09-01
A 2025 study identifies PP2A-dependent phosphorylation of Atg13 and activation of Atg1 as a regulatory route linking autophagy to Candida albicans biofilm formation and antifungal resistance. Its mutant, pharmacologic, oxidative-stress, imaging, and mouse oral-infection experiments suggest that disrupting this pathway may improve antifungal responses, although the findings remain specific to C. albicans biofilms and the tested infection model.
-
Sulfaphenazole Restores Vasodilation in Diabetic Mice
2026-09-01
This study identified CYP 2C-derived oxidative stress as a pharmacologically tractable contributor to endothelial dysfunction in db/db mice. Sulfaphenazole restored acetylcholine-dependent vasodilation, reduced systemic oxidative stress, and increased nitric oxide bioavailability without lowering plasma glucose, linking cytochrome P450 activity to vascular injury independently of glycemic control.
-
TBK1, Microglial Pyroptosis, and Painful Diabetic Neuropathy
2026-08-31
Liao et al. identify TANK-binding kinase 1 (TBK1) as a mechanistic driver of painful diabetic neuropathy through activation of NF-κB, NLRP3 inflammasome signaling, and microglial pyroptosis in the spinal dorsal horn. Their combination of TBK1 siRNA, caspase-1 inhibition, and amlexanox treatment links this pathway to both pain hypersensitivity and peripheral nerve injury, providing a focused framework for neuroinflammatory diabetes research.
-
Dhcr7 Knockout Grass Carp and GCRV Resistance
2026-08-31
A 2026 Aquaculture Reports study used CRISPR/Cas9 to establish Dhcr7 as an in vivo determinant of resistance to lethal GCRV-II infection in grass carp. Dhcr7 disruption improved survival, strengthened Irf3-associated antiviral responses, reduced viral burden and hepatopancreas injury, while not producing detectable defects in measured growth or muscle morphology.
-
Patient-Derived 3D Spheroids in Prostate Cancer
2026-08-30
Linxweiler and colleagues established viable three-dimensional spheroid cultures from organ-confined prostate cancer tissue collected during radical prostatectomy, addressing a major gap between metastatic cell lines and primary disease biology. The model retained key epithelial and prostate cancer markers, tolerated cryopreservation, and displayed differential responses to androgen-receptor-directed and cytotoxic drugs, supporting its use in translational prostate cancer research.
-
Scutellarin, Cathepsin D, and I/R Injury
2026-08-29
A 2025 Frontiers in Pharmacology study identifies cathepsin D-dependent restoration of autophagy-lysosomal function as a mechanism by which scutellarin protects endothelium during ischemia/reperfusion injury. Genetic knockdown and pharmacological inhibition with Pepstatin A together support cathepsin D as a necessary mediator, while also defining important limits for translating the findings beyond the experimental models.
-
BKT140 (BL-8040) CXCR4 Research Workflows
2026-08-28
BKT140, also called BL-8040, enables functional CXCR4 studies that connect chemotaxis, apoptosis, tumor microenvironment biology, and stem cell mobilization. This practical guide outlines assay setup, formulation choices, translational applications, and troubleshooting strategies for oncology research.
-
Fluconazole Beyond Ergosterol: A Translational Roadmap
2026-08-28
Fluconazole remains a powerful mechanistic probe for ergosterol disruption, Candida biology, and antifungal drug resistance research. New evidence on the gut-secreted methyltransferase METTL9 adds a complementary host-defense dimension, suggesting how researchers can use fluconazole perturbation alongside nutritional-immunity assays to distinguish fungal adaptation from mucosal protection.
-
JC-1 and Ferroptosis: Reading Mitochondrial Stress
2026-08-27
JC-1 converts mitochondrial membrane potential changes into a red-to-green fluorescence signal that can strengthen ferroptosis, apoptosis detection, and cellular bioenergetics studies. This article explains how to interpret the probe as one component of a rigorous, multi-readout strategy inspired by pulmonary fibrosis research.
-
Oteseconazole: From CYP51 Selectivity to Assay Meaning
2026-08-27
Oteseconazole (VT-1161) is a selective tetrazole CYP51 inhibitor with strong activity across clinically relevant Candida species. This evidence-led guide explains how to interpret its mechanism, susceptibility data, resistance relevance, and translational value without conflating screening results with clinical conclusions.
-
Dorsomorphin (Compound C): AMPK and BMP Research
2026-08-26
Dorsomorphin, also called Compound C, is a reversible ATP-competitive AMPK inhibitor with additional activity against BMP signaling. Its dual pharmacology supports studies of metabolic signaling, autophagy regulation, cellular differentiation, and iron metabolism modulation, but it requires pathway-specific controls.